Quidelortho Corporation ( (QDEL) ) has released its Q4 earnings. Here is a breakdown of the information Quidelortho Corporation presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
QuidelOrtho Corporation is a leading global provider of innovative in-vitro diagnostic technologies, specializing in point-of-care settings, clinical labs, and transfusion medicine to offer fast and reliable diagnostics solutions.
QuidelOrtho Corporation has reported its financial results for the fourth quarter and full-year 2024, highlighting a strong finish to the year despite challenges in COVID-19 and influenza revenue declines. The company has also issued financial guidance for 2025, focusing on expanding adjusted EBITDA margins.
In the fourth quarter of 2024, QuidelOrtho’s revenue stood at $708 million, reflecting a decrease from the previous year due to reduced COVID-19 and influenza revenues. Non-respiratory revenues remained flat, while labs revenue saw a growth of 4%. The company reported a GAAP net loss of $153 million for the quarter, significantly impacted by integration-related charges and a goodwill impairment. For the full year, the company reported a total revenue of $2.8 billion, with a notable decrease in respiratory revenues. Despite these challenges, the company achieved adjusted EBITDA of $150 million for the quarter and $543 million for the full year.
Looking forward, QuidelOrtho has set its 2025 financial guidance with projected revenues between $2.60 billion and $2.81 billion. The company anticipates adjusted EBITDA to range from $575 million to $615 million, with an adjusted EBITDA margin of 22%. QuidelOrtho is optimistic about its cost-saving initiatives and aims for incremental margin improvements moving into 2025 and beyond.
The company’s management remains focused on enhancing operational efficiency and leveraging its recurring revenue business model to maintain positive financial momentum as they navigate the evolving market landscape.
